dalteparin has been researched along with Gastrointestinal Hemorrhage in 22 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Gastrointestinal Hemorrhage: Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Little is known about the efficacy of proton pump inhibitors compared with H(2) receptor antagonists in preventing adverse upper gastrointestinal complications in patients with acute coronary syndrome (ACS) or ST elevation myocardial infarction (STEMI) receiving aspirin, clopidogrel, and enoxaparin or thrombolytics." | 9.16 | Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction. ( Chan, K; Chu, WM; Keung, KK; Kng, C; Kwan, A; Lam, KF; Lau, YK; Li, A; Ng, FH; Tunggal, P; Wong, BC, 2012) |
| "The combination of aspirin, clopidogrel, and enoxaparin (combination therapy) is the standard treatment for acute coronary syndrome but is associated with gastrointestinal bleeding." | 7.74 | Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome. ( Chang, CM; Chu, WM; Lam, KF; Lau, YK; Ng, FH; Wong, BC; Wong, SY, 2008) |
| "Little is known about the efficacy of proton pump inhibitors compared with H(2) receptor antagonists in preventing adverse upper gastrointestinal complications in patients with acute coronary syndrome (ACS) or ST elevation myocardial infarction (STEMI) receiving aspirin, clopidogrel, and enoxaparin or thrombolytics." | 5.16 | Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction. ( Chan, K; Chu, WM; Keung, KK; Kng, C; Kwan, A; Lam, KF; Lau, YK; Li, A; Ng, FH; Tunggal, P; Wong, BC, 2012) |
| "The combination of aspirin, clopidogrel, and enoxaparin (combination therapy) is the standard treatment for acute coronary syndrome but is associated with gastrointestinal bleeding." | 3.74 | Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome. ( Chang, CM; Chu, WM; Lam, KF; Lau, YK; Ng, FH; Wong, BC; Wong, SY, 2008) |
| "Bleeding was predominantly gastrointestinal or intracranial." | 2.82 | Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. ( Albaladejo, P; Beyer-Westendorf, J; Bronson, MD; Cohen, AT; Conley, PB; Connolly, SJ; Crowther, M; Curnutte, JT; Eikelboom, JW; Gibson, CM; Gold, A; Goodman, S; Leeds, J; Lim, WT; Lopez-Sendon, J; Lu, G; Meeks, B; Middeldorp, S; Milling, TJ; Nakamya, J; Schmidt, J; Siegal, DM; Verhamme, P; Wiens, BL; Zotova, E, 2016) |
| "Internal carotid artery stenosis was asymptomatic in 55% and symptomatic in 45%." | 2.73 | Safety and efficacy of intravenous enoxaparin for carotid endarterectomy: a prospective randomized pilot trial. ( Assadian, A; Hagmüller, GW; Hübl, W; Klingler, A; Knöbl, P; Pfaffelmeyer, N; Senekowitsch, C, 2008) |
| "The management of a patient with venous thrombosis with perinephric hematoma post renal biopsy can be difficult if occurred." | 1.72 | Double trouble - management of perinephric hematoma and renal vein thrombosis post percutaneous renal biopsy. ( Daud, MAM; Kamarudin, MI; Nadarajan, C, 2022) |
| ": Lupus anticoagulant hypoprothrombinemia syndrome (LAHS) is a rare disorder characterized by development of lupus anticoagulant and antiprothrombin antibodies." | 1.48 | Fatal pulmonary embolism and pulmonary hemorrhage in lupus anticoagulant hypoprothrombinemia syndrome: a case report and review of literature. ( Chen, X; Cunningham, MT; Nedved, D; Plapp, FV, 2018) |
| "SVT favors the relapse of esophageal varices, but rebleeding can be effectively prevented by standard scheduled band ligations." | 1.38 | Splanchnic vein thrombosis and variceal rebleeding in patients with cirrhosis. ( Amitrano, L; Guardascione, MA; Lampasi, F; Lanza, AG; Manguso, F; Martino, R; Menchise, A; Scaglione, M, 2012) |
| "Gastrointestinal stromal tumors are the commonest stromal tumors of the digestive tract." | 1.36 | [Gastrointestinal stromal tumor in pregnancy and control. Case report]. ( Cuerva-González, MJ; de la Calle-Fernández, M; Lacoponi, S; Pozo-Krielinger, J, 2010) |
| " However, emerging evidence suggests that different dosing strategies may be equivalent." | 1.32 | Daily vs twice daily enoxaparin in the prevention of venous thromboembolic disorders during rehabilitation following acute spinal cord injury. ( Chen, D; Crandall, S; Hebbeler, SL; Marciniak, CM; Mendelewski, S; Nussbaum, S, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (36.36) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 4 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, Z | 1 |
| Li, S | 1 |
| Zhao, J | 1 |
| Li, J | 2 |
| Gao, Y | 1 |
| Kaya, S | 1 |
| Hatemi, I | 1 |
| Hamzaoglu, I | 1 |
| Uzunismail, H | 1 |
| Kamarudin, MI | 1 |
| Nadarajan, C | 1 |
| Daud, MAM | 1 |
| Oh, HJ | 1 |
| Ryu, KH | 1 |
| Park, BJ | 1 |
| Yoon, BH | 1 |
| Hoe, V | 1 |
| Kinnear, N | 1 |
| Christidis, D | 1 |
| O'Connell, H | 1 |
| Chen, X | 1 |
| Nedved, D | 1 |
| Plapp, FV | 1 |
| Cunningham, MT | 1 |
| Sengupta, N | 1 |
| Feuerstein, JD | 1 |
| Patwardhan, VR | 1 |
| Tapper, EB | 1 |
| Ketwaroo, GA | 1 |
| Thaker, AM | 1 |
| Leffler, DA | 1 |
| Connolly, SJ | 1 |
| Milling, TJ | 1 |
| Eikelboom, JW | 1 |
| Gibson, CM | 1 |
| Curnutte, JT | 1 |
| Gold, A | 1 |
| Bronson, MD | 1 |
| Lu, G | 1 |
| Conley, PB | 1 |
| Verhamme, P | 1 |
| Schmidt, J | 1 |
| Middeldorp, S | 1 |
| Cohen, AT | 1 |
| Beyer-Westendorf, J | 1 |
| Albaladejo, P | 1 |
| Lopez-Sendon, J | 1 |
| Goodman, S | 1 |
| Leeds, J | 1 |
| Wiens, BL | 1 |
| Siegal, DM | 1 |
| Zotova, E | 1 |
| Meeks, B | 1 |
| Nakamya, J | 1 |
| Lim, WT | 1 |
| Crowther, M | 1 |
| Kalu, ON | 1 |
| Al-Khoury, G | 1 |
| Reck, CA | 1 |
| Velcek, F | 1 |
| Goldhaber, SZ | 1 |
| Bechmann, LP | 1 |
| Sichau, M | 1 |
| Wichert, M | 1 |
| Gerken, G | 1 |
| Kröger, K | 1 |
| Hilgard, P | 1 |
| Northup, PG | 1 |
| Intagliata, NM | 1 |
| Cuerva-González, MJ | 1 |
| Lacoponi, S | 1 |
| de la Calle-Fernández, M | 1 |
| Pozo-Krielinger, J | 1 |
| Ng, FH | 2 |
| Tunggal, P | 1 |
| Chu, WM | 2 |
| Lam, KF | 2 |
| Li, A | 1 |
| Chan, K | 1 |
| Lau, YK | 2 |
| Kng, C | 1 |
| Keung, KK | 1 |
| Kwan, A | 1 |
| Wong, BC | 2 |
| Amitrano, L | 1 |
| Guardascione, MA | 1 |
| Scaglione, M | 1 |
| Menchise, A | 1 |
| Martino, R | 1 |
| Manguso, F | 1 |
| Lanza, AG | 1 |
| Lampasi, F | 1 |
| Hebbeler, SL | 1 |
| Marciniak, CM | 1 |
| Crandall, S | 1 |
| Chen, D | 1 |
| Nussbaum, S | 1 |
| Mendelewski, S | 1 |
| DeWitt, E | 1 |
| Adams, J | 1 |
| Bostwick, C | 1 |
| O'Dell, M | 1 |
| Wessinger, S | 1 |
| Kaplan, M | 1 |
| Choi, L | 1 |
| Williams, M | 1 |
| Lau, C | 1 |
| Sharp, L | 1 |
| Crowell, MD | 1 |
| Keshavarzian, A | 1 |
| Jones, MP | 1 |
| Wong, SY | 1 |
| Chang, CM | 1 |
| Assadian, A | 1 |
| Knöbl, P | 1 |
| Hübl, W | 1 |
| Senekowitsch, C | 1 |
| Klingler, A | 1 |
| Pfaffelmeyer, N | 1 |
| Hagmüller, GW | 1 |
| Raithel, M | 1 |
| Haibach, M | 1 |
| Kremenevski, I | 1 |
| Arnold, E | 1 |
| Ringwald, J | 1 |
| Xiang, Y | 1 |
| Sun, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation[NCT03021928] | Phase 3 | 200 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| Prospective, Open-Label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor Who Have Acute Major Bleeding (ANNEXA-4)[NCT02329327] | Phase 3 | 479 participants (Actual) | Interventional | 2015-04-10 | Completed | ||
| Famotidine Compared With Esomeprazole in the Prevention of Ulcer Complications in Patients With Acute Coronary Syndrome or Myocardial Infarction[NCT00683111] | Phase 4 | 500 participants (Anticipated) | Interventional | 2008-07-31 | Completed | ||
| Beijing Tiantan Hospital,Capital Medical University.[NCT02317445] | 472 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. The change from baseline was calculated as the reduction in anti-fXa activity from baseline to the on-treatment nadir (that is, the minimum value between end of bolus and end of infusion). Percent reduction was calculated as the ratio between the maximum change from baseline and the baseline value, multiplied by 100. (NCT02329327)
Timeframe: Baseline, 12 Hours (post infusion)
| Intervention | Percent Change (Median) |
|---|---|
| FXa Inhibitor: Apixaban | -93.3 |
| FXa Inhibitor: Rivaroxaban | -94.1 |
| FXa Inhibitor: Edoxaban | -71.3 |
| FXa Inhibitor: Enoxaparin | -75.41 |
| FXa Inhibitor: Rivaroxaban - Additional Participants | -96.3 |
Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons. These ratings were based on pre-specified criteria that were included in the EAC Charter. The EAC was blinded to anti-fXa activity levels. Participant results were classified as either success or failure based on the hemostatic efficacy rating (success = excellent/good, failure = poor/none). Participants rated by the EAC as non-evaluable due to administrative reasons were excluded from the analysis of hemostatic efficacy. (NCT02329327)
Timeframe: 12 Hours (post infusion)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Excellent/Good | Poor/None | |
| Andexanet: High Dose | 54 | 17 |
| Andexanet: High Dose - Additional Participant | 1 | 0 |
| Andexanet: Low Dose | 218 | 51 |
| Andexanet: Low Dose - Additional Participant | 1 | 0 |
| Bleed Type: Gastrointestinal | 61 | 13 |
| Bleed Type: Intracranial Hemorrhage | 193 | 51 |
| Bleed Type: Intracranial Hemorrhage - Additional Participants | 2 | 0 |
| Bleed Type: Other | 18 | 4 |
| FXa Inhibitor: Apixaban | 134 | 35 |
| FXa Inhibitor: Edoxaban | 22 | 6 |
| FXa Inhibitor: Enoxaparin | 14 | 2 |
| FXa Inhibitor: Rivaroxaban | 102 | 25 |
| FXa Inhibitor: Rivaroxaban - Additional Participants | 2 | 0 |
| Overall | 272 | 68 |
This outcome measure assessed the relationship between hemostatic efficacy and anti-fXa activity in participants receiving an FXa inhibitor who had acute major bleeding. Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons. (NCT02329327)
Timeframe: Baseline, 12 Hours (post infusion)
| Intervention | Percent Change (Median) |
|---|---|
| Excellent/Good | |
| FXa Inhibitor: Rivaroxaban - Additional Participants | -96.3 |
This outcome measure assessed the relationship between hemostatic efficacy and anti-fXa activity in participants receiving an FXa inhibitor who had acute major bleeding. Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons. (NCT02329327)
Timeframe: Baseline, 12 Hours (post infusion)
| Intervention | Percent Change (Median) | |
|---|---|---|
| Excellent/Good | Poor/None | |
| FXa Inhibitor: Apixaban | -93.4 | -93.3 |
| FXa Inhibitor: Edoxaban | -75.8 | -65.2 |
| FXa Inhibitor: Enoxaparin | -75.20 | -78.44 |
| FXa Inhibitor: Rivaroxaban | -94.6 | -92.4 |
1 review available for dalteparin and Gastrointestinal Hemorrhage
| Article | Year |
|---|---|
The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Fema | 2021 |
4 trials available for dalteparin and Gastrointestinal Hemorrhage
| Article | Year |
|---|---|
Anticoagulation therapy early is safe in portal vein thrombosis patients with acute variceal bleeding: a multi-centric randomized controlled trial.
Topics: Albumins; Anticoagulants; Esophageal and Gastric Varices; Fibrosis; Gastrointestinal Hemorrhage; Hum | 2023 |
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In | 2016 |
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In | 2016 |
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In | 2016 |
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In | 2016 |
Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction.
Topics: Acute Coronary Syndrome; Aged; Anti-Ulcer Agents; Aspirin; Chi-Square Distribution; Clopidogrel; Dou | 2012 |
Safety and efficacy of intravenous enoxaparin for carotid endarterectomy: a prospective randomized pilot trial.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Loss, Surgical; Blood Transfusion; Brain Ische | 2008 |
17 other studies available for dalteparin and Gastrointestinal Hemorrhage
| Article | Year |
|---|---|
Massive haemorrhage induced by low molecular weight heparin in a patient with steroid refractory ulcerative colitis.
Topics: Adult; Anticoagulants; Colitis, Ulcerative; Female; Gastrointestinal Hemorrhage; Humans; Nadroparin; | 2004 |
Double trouble - management of perinephric hematoma and renal vein thrombosis post percutaneous renal biopsy.
Topics: Adult; Biopsy; Enoxaparin; Gastrointestinal Hemorrhage; Hematoma; Hematuria; Humans; Kidney Diseases | 2022 |
Rectus sheath haematoma causing ureteric obstruction.
Topics: Adenocarcinoma; Aged, 80 and over; Anticoagulants; Colonic Neoplasms; Enoxaparin; Female; Gastrointe | 2018 |
Fatal pulmonary embolism and pulmonary hemorrhage in lupus anticoagulant hypoprothrombinemia syndrome: a case report and review of literature.
Topics: Aged; Anticoagulants; Antiphospholipid Syndrome; Enoxaparin; Fatal Outcome; Female; Gastrointestinal | 2018 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; E | 2015 |
Submucosal hematoma presenting as small bowel obturator obstruction in a patient on low-molecular-weight heparin.
Topics: Anastomosis, Surgical; Child, Preschool; Enoxaparin; Female; Follow-Up Studies; Gastrointestinal Hem | 2008 |
Ask the doctor. I am due to have a colonoscopy. My cardiologist told me that I will need to stop taking Coumadin, which I take for atrial fibrillation, a few days before the procedure and get some injections. Is this really necessary?
Topics: Anticoagulants; Colonoscopy; Dalteparin; Enoxaparin; Gastrointestinal Hemorrhage; Humans; Preoperati | 2009 |
Low-molecular-weight heparin in patients with advanced cirrhosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin III; Blood Coagulation; Dru | 2011 |
Anticoagulation in cirrhosis patients: what don't we know?
Topics: Anticoagulants; Antithrombin III; Blood Coagulation; Drug Monitoring; Enoxaparin; Esophageal and Gas | 2011 |
[Gastrointestinal stromal tumor in pregnancy and control. Case report].
Topics: Adult; Anticoagulants; Cesarean Section; Embolism, Amniotic Fluid; Emergencies; Enoxaparin; Female; | 2010 |
Splanchnic vein thrombosis and variceal rebleeding in patients with cirrhosis.
Topics: Aged; Anticoagulants; Chi-Square Distribution; Endoscopy, Gastrointestinal; Enoxaparin; Esophageal a | 2012 |
Daily vs twice daily enoxaparin in the prevention of venous thromboembolic disorders during rehabilitation following acute spinal cord injury.
Topics: Drug Administration Schedule; Enoxaparin; Female; Fibrinolytic Agents; Gastrointestinal Hemorrhage; | 2004 |
Gastrointestinal bleeding in an elderly patient with a recent hip replacement.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Contraindications; Diagnosi | 2004 |
Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Black or African American; B | 2006 |
Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Drug | 2008 |
[Modern anticoagulation with factor Xa inhibitors in oncology: is the gastrointestinal bleeding rate (also) decisive?]
Topics: Anticoagulants; Dalteparin; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Humans; Neoplasms; Pr | 2023 |
A case report of pulmonary arterial hypertension in pregnancy and complications of anticoagulation therapy.
Topics: Adult; Anticoagulants; Antihypertensive Agents; Cardiovascular Agents; Dalteparin; Epoprostenol; Fem | 2018 |